Approval · Notice of Compliance 9171 · 2007
ERAXIS: Notice of Compliance 9171
Issued November 14, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9171
- Date
- November 14, 2007
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Antifungal agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ERAXIS | 02302160 | Cancelled Post Market |
Medicinal ingredients
- ANIDULAFUNGIN 100 MG per VIAL